Folate Augmentation of Treatment -- Evaluation for Depression (FolATED): protocol of a randomised controlled trial

Roberts, Seren Haf; Bedson, Emma; Hughes, Dyfrig; Lloyd, Keith; Moat, Stuart; Pirmohamed, Munir; Slegg, Gary; Tranter, Richard; Whitaker, Rhiannon; Wilkinson, Clare; Russell, Ian
January 2007
BMC Psychiatry;2007, Vol. 7, p65
Academic Journal
Background: Clinical depression is common, debilitating and treatable; one in four people experience it during their lives. The majority of sufferers are treated in primary care and only half respond well to active treatment. Evidence suggests that folate may be a useful adjunct to antidepressant treatment: 1) patients with depression often have a functional folate deficiency; 2) the severity of such deficiency, indicated by elevated homocysteine, correlates with depression severity, 3) low folate is associated with poor antidepressant response, and 4) folate is required for the synthesis of neurotransmitters implicated in the pathogenesis and treatment of depression. Methods/Design: The primary objective of this trial is to estimate the effect of folate augmentation in new or continuing treatment of depressive disorder in primary and secondary care. Secondary objectives are to evaluate the cost-effectiveness of folate augmentation of antidepressant treatment, investigate how the response to antidepressant treatment depends on genetic polymorphisms relevant to folate metabolism and antidepressant response, and explore whether baseline folate status can predict response to antidepressant treatment. Seven hundred and thirty patients will be recruited from North East Wales, North West Wales and Swansea. Patients with moderate to severe depression will be referred to the trial by their GP or Psychiatrist. If patients consent they will be assessed for eligibility and baseline measures will be undertaken. Blood samples will be taken to exclude patients with folate and B12 deficiency. Some of the blood taken will be used to measure homocysteine levels and for genetic analysis (with additional consent). Eligible participants will be randomised to receive 5 mg of folic acid or placebo. Patients with B12 deficiency or folate deficiency will be given appropriate treatment and will be monitored in the 'comprehensive cohort study'. Assessments will be at screening, randomisation and 3 subsequent follow-ups. Discussion: If folic acid is shown to improve the efficacy of antidepressants, then it will provide a safe, simple and cheap way of improving the treatment of depression in primary and secondary care. Trial registration: Current controlled trials ISRCTN37558856


Related Articles

  • Adjuvant Folate with Escitalopram Treatment and Homocystein, Folate, Vitamin B-12 Levels in Patients with Major Depressive Disorder. BaşoğIu, Cengiz; Ateş, M. Alpay; AIgüI, Ayhan; İpçioğIu, Osman Metin; Geçici, Ömer; Yılmaz, Onur; Semiz, Ümit Başar; Ebrinç, Servet; Gülsün, Murat; Özcan, Ömer; KıIıç, Selim; Çetin, Mesut // Klinik Psikofarmakoloji Bulteni;Jun2009, Vol. 19 Issue 2, p135 

    Objective: Folate supplementation in Major Depressive Disorder (MDD) has been investigated in clinical studies with promising results. The primary objective of this trial was to study the effect of adjuvant folate treatment with escitalopram in MDD patients. Secondary objectives were to evaluate...

  • 15. Folate and folic acid: 15.4 Recommended nutrient intakes for folate.  // Vitamin & Mineral Requirements in Human Nutrition;2004, p295 

    Chapter 15.4 of the book "Vitamin & Mineral Requirements in Human Nutrition" is presented. This section presents recommended nutriet intakes for folate. It identifies three states of folate nutrition: folate adequacy, impending folate deficiency and overt folate deficiency. The role of the...

  • B Vitamins May Spell Migraine Relief.  // Tufts University Health & Nutrition Letter;Jul2009, Vol. 27 Issue 5, p8 

    The article focuses on the benefit of B-vitamin supplement intake in lowering the frequency and severity of migraines. It notes that B-vitamins helped in lowering the levels of the amino acid homocysteine during migraine attacks. It notes that researchers Lyn Griffiths and colleagues of the...

  • Get a Boost From B. LINDNER, LARRY // Arthritis Today;Nov2010, Vol. 24 Issue 6, p28 

    The article reports on the findings of a study conducted by Rush University Medical Center in Chicago, Illinois that B vitamins play a role in warding off depression.

  • Influence of the cystathionine β-synthase 844ins68 and methylenetetrahydrofolate reductase 677C>T polymorphisms on folate and homocysteine concentrations. Summers, Carolyn M.; Hammons, Andrea L.; Mitchell, Laura E.; Woodside, Jayne V.; Yarnell, John W. G.; Young, Ian S.; Evans, Alun; Whitehead, Alexander S. // European Journal of Human Genetics;Aug2008, Vol. 16 Issue 8, p1010 

    A high homocysteine, low folate phenotype is a feature of many diseases. The effect of the cystathionine β-synthase (CBS) 844ins68 polymorphism on homocysteine and folate concentrations was examined alone and in the context of the 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C>T...

  • METHIONINE SYNTHASE REDUCTASE (MTRR) GENE 66G>A POLYMORPHISM AS A POSSIBLE RISK FACTOR FOR RECURRENT SPONTANEOUS ABORTION. Popp, R. A.; Trifa, A. P.; Militaru, Mariela; Crisan, Tania Octavia; Petrisor, Felicia; Farcas, M. F.; Csernik, F. A.; Pop, I. V. // Annals of the Romanian Society for Cell Biology;2009, Vol. 14 Issue 1, p28 

    Low dietary folate intake has been blamed for many pathologies including cancers, thrombophilia, congenital anomalies (e.g. neural tube defects) and recurrent spontaneous abortions (RSA). An important biological function of folates, which is closely related to homocysteine levels, is to provide...

  • Homocystinuria: Vitamin B Dependent of Not? Frimpler, George W. // Annals of Internal Medicine;Jul69, Vol. 71 Issue 1, p209 

    Editorial. Provides information on homocystinuria. Discussion on homocysteine; Therapeutic use of vitamin B for homocystinuria; Details of various clinical trials on homocyctinuria.

  • B vitamins not for cognition.  // Clinical Advisor;Sep2014, Vol. 17 Issue 9, p26 

    No abstract available.

  • Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. Tansey, Katherine E.; Guipponi, Michel; Perroud, Nader; Bondolfi, Guido; Domenici, Enrico; Evans, David; Hall, Stephanie K.; Hauser, Joanna; Henigsberg, Neven; Xiaolan Hu; Jerman, Borut; Maier, Wolfgang; Mors, Ole; O'Donovan, Michael; Peters, Tim J.; Placentino, Anna; Rietschel, Marcella; Souery, Daniel; Aitchison, Katherine J.; Craig, Ian // PLoS Medicine;Oct2012, Vol. 9 Issue 10, p1 

    Background: It has been suggested that outcomes of antidepressant treatment for major depressive disorder could be significantly improved if treatment choice is informed by genetic data. This study aims to test the hypothesis that common genetic variants can predict response to antidepressants...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics